Controversy between first French lab and FDA

31 May

A controversy about efficacy and safety with respect to immunogenicity and potential adverse effects of generics of low molecular weight heparin and lovenox the brand product is rising between Food and Drug Administration and Sanofi our first French pharmaceutical firm. Its a struggle for life for the French block buster.

American senate accuses French lab to spent a lot of money and to have financial ties with an american scientist and a medical society who alerted on the possibility of non equivalence between the generic and the brand product.

Dr Tapson cited in the Wall Street Journal is a Professor of medicine consultant for Aventis


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: